II. Class
- Anti-retroviral agent
-
Non-Nucleoside Reverse Transcriptase Inhibitor
- First generation agent
III. Indications: HIV and AIDS
- Most commonly used NNRTI in 2011 and available in combination (Atripla)
IV. Dosing
- Adult
- Efavirenz 600 mg qhs
- Child
- Weight 10-14 kg: 200 mg qhs
- Weight 15-19 kg: 250 mg qhs
- Weight 20-24 kg: 300 mg qhs
- Weight 25-32 kg: 350 mg qhs
- Weight 32-40 kg: 400 mg qhs
V. Adverse Effects
VI. Pregnancy
- Potentially Teratogenic
VII. Drug Interactions
- Take on empty Stomache at bedtime
- Induces CYP3A4 enzyme
- Decreases serum levels of some Protease Inhibitors
- Avoid concurrent use of Saquinavir
- Raise dose of Indinavir to 1000 mg PO q8h
- Decreases some Macrolide levels
- Decreases Clarithromycin level
- Azithromycin not effected
VIII. Labs
- Causes False Positive drug screen for Cannabinoids, Benzodiazepines
Images: Related links to external sites (from Bing)
Related Studies
efavirenz (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
EFAVIRENZ-EMTRICITABINE-TENOFOV DISOP FUM 600-200-300 MG TAB | Generic | $4.50 each |